SESSION HIGHLIGH FROM:
13th Annual Medical Device Coverage and Reimbursement Conference

July 24-25, 2017 | Chicago, IL

Hotel Chicago Downtown

Please Complete the Form to Download the Agenda

MASTER CLASS: GENERATING ROBUST & IMPACTFUL CLINICAL EVIDENCE NECESSARY TO SUPPORT REIMBURSEMENT

With HTA requests to be provided with meaningful scientific and economic data pertinent to the medical product, reimbursement executives are commonly collecting evidence from clinical teams to ultimately support value dossiers. Forward-thinking corporations have initiated collaborations with clinical teams and continue to develop clinical studies integrating health economic outcomes to address and streamline preparation of dossiers for reimbursement. In this proactive effort, it is critical to clearly determine what type of clinical evidence can be used to demonstrate product effectiveness and cost-benefit ratios specific to the target market, in addition to the overall amount of data to convey to decision makers in order to establish and meet target evidence end-points.

PART 1: INDUSTRY PERSPECTIVE

• Defining the nature, quality & amount of necessary evidence

• Integrating reimbursement evidence needs in clinical strategy

• Study designs fulfilling reimbursement evidence goals & RCTs

• Clinical data translation into payer-relevant evidence

Presented By: Sharon Whalen, Sr. Director, Reimbursement & Policy at Acelity

PART 2: HTA PERSPECTIVE

• Defining type, quality, & amount of evidence needed: PICOTS framework

• Best evidence & study design: it doesn’t always have to be an RCT

• Understanding type of economic evidence payers & providers value

• Formulating key questions of interest to payers & providers

Presented By: Vivian Coates, Vice President, Information Services & Health Technology Assessment ECRI

 

WE GUARANTEE 100% PRIVACY, YOUR INFORMATION WILL NOT BE SHARED